Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC

Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Chengxiang, He, Yayi, Xia, Haoran, Zhang, Helin, Zhang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735538/
https://www.ncbi.nlm.nih.gov/pubmed/31564915
http://dx.doi.org/10.2147/OTT.S218321
_version_ 1783450370272395264
author Yi, Chengxiang
He, Yayi
Xia, Haoran
Zhang, Helin
Zhang, Peng
author_facet Yi, Chengxiang
He, Yayi
Xia, Haoran
Zhang, Helin
Zhang, Peng
author_sort Yi, Chengxiang
collection PubMed
description Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on NSCLC are still being explored. In this review, we summarized the research progress and outline the issues need to be solved on adjuvant and neoadjuvant immunotherapies in NSCLC.
format Online
Article
Text
id pubmed-6735538
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67355382019-09-27 Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC Yi, Chengxiang He, Yayi Xia, Haoran Zhang, Helin Zhang, Peng Onco Targets Ther Review Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on NSCLC are still being explored. In this review, we summarized the research progress and outline the issues need to be solved on adjuvant and neoadjuvant immunotherapies in NSCLC. Dove 2019-09-06 /pmc/articles/PMC6735538/ /pubmed/31564915 http://dx.doi.org/10.2147/OTT.S218321 Text en © 2019 Yi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Yi, Chengxiang
He, Yayi
Xia, Haoran
Zhang, Helin
Zhang, Peng
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
title Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
title_full Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
title_fullStr Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
title_full_unstemmed Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
title_short Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
title_sort review and perspective on adjuvant and neoadjuvant immunotherapies in nsclc
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735538/
https://www.ncbi.nlm.nih.gov/pubmed/31564915
http://dx.doi.org/10.2147/OTT.S218321
work_keys_str_mv AT yichengxiang reviewandperspectiveonadjuvantandneoadjuvantimmunotherapiesinnsclc
AT heyayi reviewandperspectiveonadjuvantandneoadjuvantimmunotherapiesinnsclc
AT xiahaoran reviewandperspectiveonadjuvantandneoadjuvantimmunotherapiesinnsclc
AT zhanghelin reviewandperspectiveonadjuvantandneoadjuvantimmunotherapiesinnsclc
AT zhangpeng reviewandperspectiveonadjuvantandneoadjuvantimmunotherapiesinnsclc

Ejemplares similares